Get started
Author

Simone Foderaro

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 49
Network approach in liquidomics landscape
2023 · Daniele Santini, Andrea Botticelli, et al. · Journal of Experimental & Clinical Cancer Research · 37
PDF
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
2022 · Francesco Pantano, Francesca Zalfa, et al. · Cancers · 33
PDF
Bone metastases from urothelial carcinoma. The dark side of the moon
2021 · Marco Stellato, Daniele Santini, et al. · Journal of bone oncology · 22
PDF
Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
2024 · Crescenzo Massaro, Hilal N. Sensoy, et al. · Clinical Cancer Research · 13
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
2025 · Amin H Nassar, Sarah Abou Alaiwi, et al. · Journal for ImmunoTherapy of Cancer · 8
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis
2026 · L. Sisca, M. G. Polito, et al. · Breast Cancer Research and Treatment · 5
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
2025 · Roberta Scafetta, Marco Donato, et al. · The Breast · 5
PDF
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non–small cell lung cancer
2026 · Silvia Cavaliere, Marta Fogolari, et al. · Journal of Translational Medicine · 2
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
2026 · Roberta Scafetta, Raffaella Troiano, et al. · European Journal of Cancer · 1
OMIP‐120: A 22‐Marker Spectral Flow Cytometry Panel for the Characterization of Major Immune Populations in Murine Bone Marrow and Osteosarcoma Tissue
2026 · Simone Foderaro, Manon Mulders, et al. · Cytometry Part A · 1
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
2026 · Roberta Scafetta, Marco Donato, et al. · The Oncologist · 1
Corrigendum to “Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: an exploratory imaging-based analysis” [J. Bone Oncol. (2026) 100795]
2026 · Mariam Grazia Polito, Consolo Andrea, et al. · Journal of bone oncology
Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis
2026 · Mariam Grazia Polito, Consolo Andrea, et al. · Journal of bone oncology
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
2026 · Talal El Zarif, Sarah Abou Alaiwi, et al. · The Oncologist
Protocol for isolation of live tumor-infiltrating immune cells from immunocompetent murine brains for high-dimensional profiling
2026 · Aimée du Chatinier, Leyla Rigamonti, et al. · STAR Protocols
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
2026 · Roberta Scafetta, Raffaella Troiano, et al. · European Journal of Cancer
Additional file 1 of Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non–small cell lung cancer
2026 · Cavaliere, Silvia, Fogolari, Marta, et al. · Figshare
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non–small cell lung cancer
2026 · Cavaliere, Silvia, Fogolari, Marta, et al. · Figshare
333P The role of denosumab in BRCA-mutated HR+/HER2- metastatic breast cancer with bone metastases: A multicenter retrospective study
2025 · R. Scafetta, M. Donato, et al. · ESMO Open
113P Dynamic changes in gut microbiota in patients with ER+/HER2- breast cancer treated with cyclin-dependent kinase 4/6 inhibitors
2025 · M. Donato, M. Fogolari, et al. · ESMO Open
PDF
A 22-Marker Spectral Flow Cytometry Panel for the Characterization of Murine Bone Marrow, Spleen and Osteosarcoma tissue
2024 · Baglio, Serena Rubina, Foderaro, Simone · Zenodo (CERN European Organization for Nuclear Research)
Supplementary Figure S4 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
2024 · Crescenzo Massaro, Hilal N. Sensoy, et al.
Supplementary Figure S3 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
2024 · Crescenzo Massaro, Hilal N. Sensoy, et al.
Supplementary Figure S6 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
2024 · Crescenzo Massaro, Hilal N. Sensoy, et al.
Works count: 37
Citation count: 177
H-index: 6
I10-index: 5
Year
Topic
Type